

DAFNE sponsorship opportunities 2020 - 2021

Background to the DAFNE programme

DAFNE (Dose Adjustment for Normal Eating) is an evidenced skills-based structured education programme in intensive insulin therapy and self management for adults with type 1 diabetes leading to improved biomedical and psychological outcomes. The programme is nationally recognised as the gold standard in structured education for type 1 diabetes.

The DAFNE programme is a not-for-profit initiative; collaboratively run by a central office of administrative staff hosted by Northumbria Healthcare NHS Foundation Trust. The Executive Board consists of front line healthcare professionals who deliver DAFNE at locations throughout the UK, as well as representatives of key stakeholder groups including DAFNE users and Diabetes UK. The programme has been delivered in the UK since February 2000 and is currently delivered in 87 diabetes services in 162 localities across the UK and Republic of Ireland by more than 1,500 DAFNE trained healthcare professionals. To date more than 50,000 adults with type 1 diabetes have completed a DAFNE course.

Sponsorship levels

There are 3 levels of sponsorship available to choose from, with benefits proportional to the level of sponsorship selected. The various levels and cost for the 2020-21 fiscal year are:

- Gold: £14,000
- Silver: £8,000
- Bronze: £3,000

There are no limits on the number of individual sponsors at each level.

Activities included in the 2020-21 sponsorship opportunity

The 6 activities shown in table 1 overleaf are included in the sponsorship opportunity depending upon the level of sponsorship. Further details for each activity can be found after table 1.

Sponsors will also be acknowledged on the home page of the DAFNE website. You may also promote your level of sponsorship on the home page of your company website - wording to be agreed. In addition to the specific benefits listed here, Sponsors will also benefit from being associated with the highly regarded DAFNE programme.

DAFNE Corporate Sponsorship Levels 2020 – 2021

Sponsorship Level	Gold	Silver	Bronze
Cost for 2020- 2021	£14,000	£8,000	£3,000

Sponsorship level recognition

		Gold	Silver	Bronze
Collaborative meeting 2020	Company name on all correspondence and on the day materials (listed alphabetically)	Yes	After Gold	After Silver
	Acknowledgement slide prior to each of the plenaries (listed alphabetically)	Yes	After Gold	After Silver
	Small promotional table in coffee / networking area [and complimentary delegate place]*	Yes [2 Delegate places]	Yes [1 Delegate place]	No
	* There will be DAFNE users (adults that have completed a 5-day DAFNE course) present at the meeting therefore your presence and literature provided on the promotional stand must take this into account.			
DAFNE educator network meetings	Company name on all meeting related material (listed alphabetically)	Yes	After Gold	No
10 DAFNE Doctor Programme Fellowships	Company name on all correspondence regarding fellowships (listed alphabetically)	Yes	No	No
DAFNE Executive Board meetings	Company name on all meeting related material (listed alphabetically)	Yes	After Gold	No
Website	Acknowledgement of sponsorship level on DAFNE website home page (listed alphabetically)	Yes	After Gold	After Silver
	Sponsorship promoted on your website home page - wording to be agreed	Yes	Yes	Yes

Table 1: Sponsorship level recognition

1. 2020 DAFNE Collaborative meeting

Sponsorship levels included

Gold, silver and bronze – refer to table 1

What is it?

This annual meeting provides an opportunity to share audit data, gain input into topical issues, share best practice and offers networking opportunities for delegates. The 2019 programme can be found in Appendix 3.

Attendee evaluation is consistently high. In June 2019, 67% of delegates provided feedback of which:

- 96% agreed they would recommend the meeting to their DAFNE colleagues
- 90% agreed they had learnt new things
- 91% agreed they had learnt things that would improve their practice


A copy of the evaluation summary for the 2019 Collaborative meeting can be obtained from the central DAFNE team upon request.

The meeting receives endorsement for CPD from the British Dietetic Association and 6 credits from the Royal College of Physicians.

Who will attend?

All DAFNE centres, including collaborators in Australia (Oz DAFNE) and Kuwait (DAFNE Q8) are invited to send 2 delegates to the annual meeting. In addition other key stakeholders, such as Diabetes UK and researchers involved in the DAFNE research programmes are invited.

One hundred and thirty nine delegates attended the 2019 Collaborative meeting; attendees can be broken down as follows:



We anticipate that between 130 and 180 delegates will attend the 2020 DAFNE Collaborative.

When and where is it?

The meeting will take place on Tuesday 30th June 2020 at The University of Manchester. The venue is selected based on central location, capacity (main meeting room and breakout rooms for the workshops) and value for money.

2. 2020 - 20 Regional educator network meetings

Sponsorship Levels included

Gold and silver – refer to table 1

What are they?

There are 87 DAFNE services in the UK and RoI, split into 6 regional networks which each meet annually. These meetings provide an opportunity to share best practice, update centres on new developments within the DAFNE programme and for dialogue between centres and the national DAFNE programme team. These meetings are also used for *ad hoc* training as and when required. Meetings are chaired by a national DAFNE trainer and assessor.

Who will attend?

All DAFNE centres are invited to send at least one delegate to each of their regional network meetings.

These meetings are provided free of charge, travel for one educator from each centre is paid for, to reduce financial barriers to attendance.

When and where are they?

Each network meets at least once every year. The meetings are usually held at NHS venues, as centrally located as possible. On occasion non-NHS venues are used; these are chosen based on location and value for money; only in extreme circumstances would hotel meeting rooms be used.

3. DAFNE Doctor programme fellowships

Sponsorship levels included

Gold – refer to table 1

What are they?

Since 2010, the DAFNE programme has offered 10 free places to attend the DAFNE Doctor Programme (DDP) and become certified DAFNE Doctors (level 1). This training programme consists of:

- Successful completion of insulin dose adjustment unit and assessment
- A 5-day observation of a DAFNE course being delivered
- Attendance at a 1 day training workshop

The DDP is currently accredited with and 6 credits from the Royal College of Physicians, although this is expected to increase due to the online training being included. Travel and accommodation costs are not included in the Fellowships.

Who can apply?

Specialist trainees years 3-6 and new Consultant Diabetologists - within 12 months of appointment to their first consultant role are invited to apply.

When and where?

There are usually between 2 and 4 DDP workshops planned in a given calendar year. Workshops are usually delivered in NHS venues in England..

4. National DAFNE Executive Board meetings

Sponsorship levels included

Gold and silver – refer to table 1

What are they?

The purpose of the Board is to promote, develop and maintain the quality of the DAFNE programme on behalf of the DAFNE Consortium.

The Board works together as a team to provide strategic leadership for the Consortium to ensure that the DAFNE Mission Statement is achieved within the terms of the DAFNE Consortium Constitution.

Who will attend?

Elected and executive members of the Board

When and where are they?

The Board usually meet 4 times per year. The meetings are either face to face or via teleconference. Face to face meetings usually held at NHS venues, as centrally located as possible. On occasion non-NHS venues are used, these are chosen on location and value for money. .

APPENDIX 1:

Working with the pharmaceutical industry

July 2019

1. Purpose

The DAFNE Executive Board (the Board) seeks to uphold our reputation for integrity, independence, impartiality and transparency in all we do. Policies to govern relationships with the pharmaceutical industry are provided by our hosting organisation (Northumbria Healthcare NHS Foundation Trust - NHCFT).

The purpose of this position statement is to demonstrate that the Board's strategic activities are not influenced by the pharmaceutical industry and to provide clear guidance about how the Board works with the pharmaceutical industry in the best interests of adults affected by type 1 diabetes.

This position statement will safeguard the reputation of both the Board and the pharmaceutical companies concerned and enable all parties to work together collaboratively to the overall benefit of people affected by type 1 diabetes.

2. Summary

The Board has a history of working with a range of pharmaceutical companies that have an interest in diabetes. We believe it is important to maintain cooperative relationships with pharmaceutical and medical device companies that manufacture and market devices, drugs and other treatments for diabetes, but under no circumstances will we permit these companies to influence our strategic direction, activities or the content of our literature.

Where possible, the Board seeks to receive support from more than one pharmaceutical or medical device company for each project and service development. This is to help prevent accusations of favouritism towards a particular company and protect our impartiality.

The following content provides detailed guidance about how the Board and pharmaceutical and medical device companies work together.

3. Guiding principles

The Board's guidelines for working with the pharmaceutical and medical device industry are based upon the following core principles:

- Equality and impartiality
- Independence and integrity
- Openness and transparency

4. Partnerships with the pharmaceutical industry equality and impartiality

4.1. The Board will not enter into a relationship designed to give one company obvious competitive advantage over another. Where possible we favour the use of funding consortia, based on two or more companies working together. However, the Board will enter into targeted strategic partnerships with individual companies if it is deemed to be in the best interest of adults with type 1 diabetes and meets the conditions set out in this document.

Independence and integrity

4.2. In order to safeguard the Board's independence, funding from pharmaceutical and medical device companies will not exceed ten per cent of the Board's total annual income; this percentage will be reviewed annually.

4.3. The Board will not accept support from companies for activities which lie outside the Board's agreed strategy for the given period. This will ensure that the strategic objectives of the Board are guided by the best interests of DAFNE and are not perceived to be being influenced by the pharmaceutical and medical device industry.

4.4. It is imperative that the high quality information, events and meetings provided by the Board are not influenced in any way by the acceptance of pharmaceutical sponsorship. The Board will withdraw from any initiative that risk jeopardising this independent stance.

4.5. The Board will not, under any circumstances, accept support from pharmaceutical companies that might be perceived as permitting the industry to influence the Board's strategic direction or activities. All decisions about the Board's strategic direction and activities will be judged solely in the best interests of DAFNE and adults affected by type 1 diabetes.

4.6. The Board will not embark on, or continue with, any sponsorship arrangement or collaborative venture that might damage its reputation.

Openness and Transparency

4.7. The Board will make every effort to ensure compliance with the sponsorship conditions of the ABPI Code of Practice for the Pharmaceutical Industry. The Board will make public all partnerships with the pharmaceutical industry through our website.

4.8. The Board will accept financial support from one or more pharmaceuticals companies when the following conditions are met:

- i. There are strong grounds for believing that a targeted partnership will result in benefit to DAFNE and adults affected by type 1 diabetes;
- ii. The Board, taking appropriate advice from relevant sources, is satisfied that no adverse publicity will accrue from accepting such support;
- iii. There is no attempt on the part of the company or companies to influence the Board strategic direction, actions or activities either explicitly or implicitly.

5. Guidelines for working together

- 5.1. When working on a joint initiative, it is helpful if a single point of contact is identified within the company concerned to liaise with a named contact at the Board.
- 5.2. Relationships with pharmaceutical companies will be managed by the National Director, on behalf of the Board.
- 5.3. No persons acting in the name of the Board can accept a personal donation from a pharmaceutical company. Any donation offered to a person(s) who are acting in the name of DAFNE, must instead be made directly to the Board and will consequently be governed by the terms of this position statement and NHCFT policies and procedures.

Information and publications

- 5.4. The Board will not permit a pharmaceutical company to influence the content of its publications, events, meetings and information.
- 5.5. The Board will retain full editorial control over all publications and printed materials sponsored by a pharmaceutical company or companies and will maintain copyright.

Product endorsement

- 5.6. The Board will not endorse, nor put itself in a position where it might be perceived to be endorsing or promoting a particular treatment or product, other than the DAFNE programme.
- 5.7. When pharmaceutical company sponsorship is accepted, the Board will ensure that an appropriate non-endorsement statement is included in any public expression of that sponsorship.

Written agreements

- 5.8. All the Board's partnerships with pharmaceutical companies will be codified in written agreements, in line with the ABPI Code of Practice for the Pharmaceutical Industry. The Board will ensure that for each relationship the ABPI Code of Practice is satisfied.
- 5.9. Written agreements should set out exactly what has been agreed, including funding in relation to every significant activity or ongoing relationship. This should include any process of reporting back to the company, or any other obligations expected of the Board.

APPENDIX 3:

DAFNE Collaborative meeting Thursday 20th June 2019 Manchester University M1 7JR

Theme of the day: Back to the future part II

08:45	Registration, coffee, posters and networking
09:30 Clyde	Chairs opening address – Dr Helen Hopkinson, Greater Glasgow and Clyde <ul style="list-style-type: none">• Housekeeping• Programme• KPI
09:40	Plenary 1: What no hoverboards? Future practice in mental health and Type 1 diabetes <ul style="list-style-type: none">• Speaker 1: Chris Garrett, Doctor in General Adult Psychiatry
10:20	Plenary 2: What's new in DAFNE Pump? <ul style="list-style-type: none">• Speaker 1: Dr Mark Evans• Speaker 2: Dr Emma Wilmot• Speaker 3: Janet Carling
11:00	Coffee break, posters and networking
11:30	Workshop 1 – Going back to predict the future! Case discussions in high risk type 1 Facilitators: Dr Chris Garrett and Anita Beckwith Workshop 2 – DAFNE pump: case discussions Facilitators: Dr Mark Evans, Dr Emma Wilmot and Janet Carling
12:30	Lunch, posters and networking
13:30	Workshops – repeat as morning session
14:30	Coffee break
14:50	Plenary 3: Communication speed plenary to include recent changes, revalidation and STP funding <ul style="list-style-type: none">• Speaker 1: Dr Helen Hopkinson• Speaker 2: Sally Woolgar• Speaker 3: Nigel Gaynor
15:50	Chairs closing address
16:00	Close

DAFNE Collaborative meeting
Thursday 20th June 2019
Manchester University M1 7JR

Workshop aims and objectives

Workshop 1 – Title: Going back to predict the future! Case discussions in high risk type 1

Facilitators: Dr Chris Garrett and Anita Beckwith

Aims: To become more confident in recognising and managing high-risk individuals with type 1 diabetes and mental health problems within the DAFNE care pathway

Learning outcome:

1. Demonstrate an understanding of the connection between red flags and mental health problems
2. Develop practical skills that can be utilised in current clinical care
3. Apply newly acquired knowledge to case studies and tailor the approach to each individual
4. Consider current care pathways and future adaptations to local services

Method: Case based discussions

Workshop 2 – DAFNE pump: Case Discussions

Facilitators: Dr Mark Evans, Dr Emma Wilmot and Janet Carling

Aims: To identify how the updated DAFNE approach can optimise use of Insulin Pump Therapy.

Learning objectives:

1. To increase confidence in optimising basal insulin, I:C ratios and correction factors
2. To increase confidence in advising on safety and insulin pumps with respect to unexplained hyperglycaemia and sick day rules

Method: Case based discussions